Implementation and Evaluation of a Fear of Cancer Recurrence Screening, Referral and Management Program
Launched by THE UNIVERSITY OF HONG KONG · Dec 12, 2023
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping cancer survivors who experience fear of their cancer coming back. The study aims to create a program that screens for this fear and provides support to manage it within regular cancer care clinics. It is designed to see how well this program works and how it can be integrated into the care that patients already receive.
To participate, patients must be between the ages of 65 and 74 and have been diagnosed with certain types of cancer, such as breast, gynecological, or colorectal cancer, within the last two years. Those who have been cancer-free for more than two years or have more advanced cancer are not eligible. If you join the study, you can expect to be part of a process that assesses your feelings about cancer recurrence and connects you with resources to help manage those feelings. This trial is currently recruiting participants, and everyone involved will contribute to improving care for future cancer survivors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients diagnosed with non-metastatic breast, gynecological, or colorectal cancer, and who have completed primary and adjuvant treatment within the past two years will be eligible for the proposed screening program.
- Exclusion Criteria:
- • All cancer patients beyond two years post-treatment; and diagnosed with metastatic cancer or non-breast, non-gynecological, and non-colorectal cancer.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Danielle Ng, PhD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported